{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:52:04Z","timestamp":1793159524732,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T00:00:00Z","timestamp":1646524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T00:00:00Z","timestamp":1646524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-022-06463-x","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T13:02:37Z","timestamp":1646571757000},"page":"1929-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare"],"prefix":"10.1007","volume":"306","author":[{"given":"Kenneth D.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda K.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Butnariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-9576","authenticated-orcid":false,"given":"Anita","family":"Afzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,6]]},"reference":[{"issue":"8","key":"6463_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3109\/00365521.2013.812141","volume":"48","author":"M Bortlik","year":"2013","unstructured":"Bortlik M, Machkova N, Duricova D et al (2013) Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study. Scand J Gastroenterol 48(8):951\u2013958. https:\/\/doi.org\/10.3109\/00365521.2013.812141","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"6463_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C Gotestam Skorpen","year":"2016","unstructured":"Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795\u2013810. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208840","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6463_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2016.10.013","volume":"152","author":"U Mahadevan","year":"2017","unstructured":"Mahadevan U, McConnell RA, Chambers CD (2017) Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology 152(2):451-462e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.013","journal-title":"Gastroenterology"},{"issue":"9","key":"6463_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/1756-185X.12860","volume":"19","author":"GS Ngian","year":"2016","unstructured":"Ngian GS, Briggs AM, Ackerman IN, Van Doornum S (2016) Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 19(9):834\u2013843. https:\/\/doi.org\/10.1111\/1756-185X.12860","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"6463_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","volume":"150","author":"GC Nguyen","year":"2016","unstructured":"Nguyen GC, Seow CH, Maxwell C et al (2016) The toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 150(3):734-757.e1. https:\/\/doi.org\/10.1053\/j.gastro.2015.12.003","journal-title":"Gastroenterology"},{"key":"6463_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1741-7015-11-174","volume":"11","author":"OH Nielsen","year":"2013","unstructured":"Nielsen OH, Loftus EV Jr, Jess T (2013) Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med 11:174\u2013174. https:\/\/doi.org\/10.1186\/1741-7015-11-174","journal-title":"BMC Med"},{"key":"6463_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12641","author":"M Rademaker","year":"2017","unstructured":"Rademaker M, Agnew K, Andrews M et al (2017) Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian psoriasis collaboration. Australas J Dermatol. https:\/\/doi.org\/10.1111\/ajd.12641","journal-title":"Australas J Dermatol"},{"issue":"2","key":"6463_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","volume":"9","author":"CJ van der Woude","year":"2015","unstructured":"van der Woude CJ, Ardizzone S, Bengtson MB et al (2015) The second european evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. ECCOJC. 9(2):107\u2013124. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju006","journal-title":"ECCOJC."},{"issue":"4","key":"6463_CR9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0002-9378(97)70298-9","volume":"177","author":"D Kornfeld","year":"1997","unstructured":"Kornfeld D, Cnattingius S, Ekbom A (1997) Pregnancy outcomes in women with inflammatory bowel disease\u2014a population-based cohort study. Am J Obstet Gynecol 177(4):942\u2013946","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"6463_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gut.2006.108324","volume":"56","author":"J Cornish","year":"2007","unstructured":"Cornish J, Tan E, Teare J et al (2007) A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56(6):830\u2013837","journal-title":"Gut"},{"issue":"9","key":"6463_CR11","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1007\/s10620-015-3677-x","volume":"60","author":"A O'Toole","year":"2015","unstructured":"O\u2019Toole A, Nwanne O, Tomlinson T (2015) Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci 60(9):2750\u20132761. https:\/\/doi.org\/10.1007\/s10620-015-3677-x","journal-title":"Dig Dis Sci"},{"issue":"9","key":"6463_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/ajg.2016.254","volume":"111","author":"A de Lima-Karagiannis","year":"2016","unstructured":"de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ (2016) The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol 111(9):1305\u20131312. https:\/\/doi.org\/10.1038\/ajg.2016.254","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"6463_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00404-020-05557-8","volume":"301","author":"A Rottenstreich","year":"2020","unstructured":"Rottenstreich A, Fridman Lev S, Rotem R et al (2020) Disease flare at prior pregnancy and disease activity at conception are important determinants of disease relapse at subsequent pregnancy in women with inflammatory bowel diseases. Arch Gynecol Obstet 301(6):1449\u20131454. https:\/\/doi.org\/10.1007\/s00404-020-05557-8","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"6463_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2796.2010.02239.x","volume":"268","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Larsson H, Pedersen L et al (2010) Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med 268(4):329\u2013337. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02239.x","journal-title":"J Intern Med"},{"issue":"8","key":"6463_CR15","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3899\/jrheum.140583","volume":"42","author":"B Bharti","year":"2015","unstructured":"Bharti B, Lee SJ, Lindsay SP et al (2015) Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project. J Rheumatol 42(8):1376\u20131382. https:\/\/doi.org\/10.3899\/jrheum.140583","journal-title":"J Rheumatol"},{"issue":"1","key":"6463_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3899\/jrheum.160929","volume":"44","author":"MA Mouyis","year":"2017","unstructured":"Mouyis MA, Thornton CC, Williams D, Giles IP (2017) Pregnancy outcomes in patients with psoriatic arthritis. J Rheumatol 44(1):128\u2013129. https:\/\/doi.org\/10.3899\/jrheum.160929","journal-title":"J Rheumatol"},{"issue":"3","key":"6463_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.14547","volume":"175","author":"R Bobotsis","year":"2016","unstructured":"Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P (2016) Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol 175(3):464\u2013472. https:\/\/doi.org\/10.1111\/bjd.14547","journal-title":"Br J Dermatol"},{"issue":"10","key":"6463_CR18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","volume":"20","author":"N Narula","year":"2014","unstructured":"Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK (2014) Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 20(10):1862\u20131869. https:\/\/doi.org\/10.1097\/MIB.0000000000000092","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"6463_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/ecco-jcc\/jjv234","volume":"10","author":"Z Shihab","year":"2016","unstructured":"Shihab Z, Yeomans ND, De Cruz P (2016) Anti-tumour necrosis factor alpha therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis 10(8):979\u2013988. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv234","journal-title":"J Crohns Colitis"},{"issue":"7","key":"6463_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apt.13960","volume":"45","author":"U Mahadevan","year":"2017","unstructured":"Mahadevan U, Vermeire S, Lasch K et al (2017) Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 45(7):941\u2013950. https:\/\/doi.org\/10.1111\/apt.13960","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"6463_CR21","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","volume":"156","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N et al (2019) Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association IBD parenthood project working group. Gastroenterology 156(5):1508\u20131524. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.022","journal-title":"Gastroenterology"},{"issue":"3","key":"6463_CR22","doi-asserted-by":"publisher","first-page":"e12454","DOI":"10.1111\/dth.12454","volume":"30","author":"T Lund","year":"2017","unstructured":"Lund T, Thomsen SF (2017) Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatol Ther 30(3):e12454. https:\/\/doi.org\/10.1111\/dth.12454","journal-title":"Dermatol Ther"},{"issue":"4","key":"6463_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12687-018-0384-2","volume":"9","author":"S Moorthie","year":"2018","unstructured":"Moorthie S, Blencowe H, Darlison MW et al (2018) Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. J Commun Genet 9(4):387\u2013396","journal-title":"J Commun Genet"},{"issue":"11","key":"6463_CR24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","volume":"113","author":"M Luu","year":"2018","unstructured":"Luu M, Benzenine E, Doret M et al (2018) Continuous anti-TNF\u03b1 use throughout pregnancy: Possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION). Am J Gastroenterol 113(11):1669\u20131677. https:\/\/doi.org\/10.1038\/s41395-018-0176-7","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"6463_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/MIB.0000000000000060","volume":"20","author":"G Broms","year":"2014","unstructured":"Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H (2014) Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 20(6):1091\u20131098. https:\/\/doi.org\/10.1097\/MIB.0000000000000060","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"6463_CR26","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/1471-0528.13946","volume":"123","author":"AW Shand","year":"2016","unstructured":"Shand AW, Chen JS, Selby W, Solomon M, Roberts CL (2016) Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes. BJOG 123(11):1862\u20131870. https:\/\/doi.org\/10.1111\/1471-0528.13946","journal-title":"BJOG"},{"issue":"4","key":"6463_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bcp.12642","volume":"80","author":"C Weber-Schoendorfer","year":"2015","unstructured":"Weber-Schoendorfer C, Oppermann M, Wacker E et al (2015) Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 80(4):727\u2013739. https:\/\/doi.org\/10.1111\/bcp.12642","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"6463_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00404-020-05644-w","volume":"302","author":"I Lavie","year":"2020","unstructured":"Lavie I, Lavie M, Doyev R, Fouks Y, Azem F, Yogev Y (2020) Pregnancy outcomes in women with inflammatory bowel disease who successfully conceived via assisted reproduction technique. Arch Gynecol Obstet 302(3):611\u2013618. https:\/\/doi.org\/10.1007\/s00404-020-05644-w","journal-title":"Arch Gynecol Obstet"},{"key":"6463_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz313","author":"A Yu","year":"2020","unstructured":"Yu A, Friedman S, Ananthakrishnan AN (2020) Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izz313","journal-title":"Inflamm Bowel Dis"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06463-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T06:06:54Z","timestamp":1667455614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06463-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6463"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06463-x","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,6]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anita Afzali is a consultant or speaker for Abbvie, Celgene\/Bristol Myers Squibb, Takeda, Janssen and Pfizer. All other authors have no conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was approved by the Ohio State University institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Given the retrospective nature of the study, a waiver of consent was granted by the Ohio State University institutional review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Given the retrospective nature of the study, a waiver of consent was granted by the Ohio State University institutional review board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}